Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

By I. Baccelli, A. Schneeweiss, S. Riethdorf, A. Stenzinger, Anja Schillert, V. Vogel, C. Klein, Massimo Saini, T. Bäuerle, M. Wallwiener and 9 more. Nature Biotechnology, 2013

1,038 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/91f5ffa92b805244c16a0442827877df1349d8a3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. C. Alix‐Panabières
2. K. Pantel
3. J. Seoane
4. Razelle Kurzrock
5. Jing Yang
6. J. Tsai
7. J. Massagué

Citations in the corpus

• Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments (2022, background): “It has been shown that BC xenografts composed of luminal BC CTCs contain MICs that are shown to induce metastasis of bone, liver, and lungs in mice [83].”
• Single-cell RNA-seq: advances and future challenges (2014, positive): “Single-cell studies are also of paramount interest in the clinics, helping to understand how an ‘outlier cell’ may determine the outcome of an infection (2), drug or antibiotic resistance (3,4) and cancer relapse (5).”
• EMERGING BIOLOGICAL PRINCIPLES OF METASTASIS (2017, neutral): “Indeed, the probability of a single CTC successfully founding a metastatic colony is vanishingly small (Baccelli et al., 2013).”
• Circulating Tumor Cell Clusters are Oligoclonal Precursors of Breast Cancer Metastasis (2014, background): “A recent study interrogating candidate genes in breast CTCs derived from a patient with breast cancer has suggested that coexpression of EpCAM, CD44, CD47, and MET identifies a subset with increased metastatic capacity (Baccelli et al., 2013).”
• Liquid Biopsy: From Discovery to Clinical Application. (2021, background): “CTC lines (25–27, 98) and xenografts (28, 30, 99) established from CTCs may also serve as valuable models to identify potential properties of metastasis-initiating cells.”
• Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis (2018, background): “Nonetheless, strong evidence to draw a mechanistic connection between CTCs and tumor metastasis is lacking clinically, although it was shown in mouse models that metastasis-initiating cells (MICs) may exist in breast cancer CTCs.(356) It has long been recognized that epithelial-tomesenchymal transit”
• Molecular profiling for precision cancer therapies (2020, background): “Therefore, single-cell analyses can lead to the detection of actionable aberrations that are implicated in metastatic spread [57], whereas tumor models derived from CTC might serve to test novel drugs or sensitivity to current standard therapies [58, 59].”
• Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis (2015, background): “…that the cancer cells in a hybrid E/M phenotype (identified by SNAIL + E-cad + in colon, and by EPCAM + CD44 + CD47 + MET + in breast cancer) can more efficiently act as seeds of metastasis (122, 123), hence establishing a clinical and prognostic relevance of the cells in the hybrid E/M phenotype.”
• Patient Derived Xenograft Models: An Emerging Platform for Translational Cancer Research (2014, background): “However, recent studies attempting to generate PDX models from circulating tumor cells have shown promising early results (69).”